Shares of CVD Equipment Corporation CVV have lost 6.7% since the company reported its earnings for the quarter ended Sept. 30, 2025, lagging the S&P 500 Index’s 1.9% gain over the same period. Over ...

Operator: Good afternoon, and welcome to the CVD Equipment Corporation Third Quarter 2025 Earnings Conference Call. As a reminder, today’s call is being recorded. We will begin with prepared remarks ...

Emmanuel Lakios, President and CEO, opened the call by stating that third quarter 2025 revenue was $7.4 million, marking a 9.6% decrease from the prior year quarter and a 44.9% increase compared to ...

CVD Equipment Corporation (NASDAQ: CVV), a leading provider of chemical vapor deposition and thermal process equipment, today announced that it will release its financial results for the third quarter ...

An international cohort study of the effect on adults of exposure to light at night found that it significantly elevates the risk for cardiovascular disease (CVD) in those aged more than 50 years. “In ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved oral semaglutide for primary and secondary prevention of CV events in high-risk adults with ...

CVD Equipment Corporation (NASDAQ: CVV), today announced that they received an order for two PVT150™ Physical Vapor Transport Systems from Stony Brook University (SBU) for their new semiconductor ...

Cardiovascular disease remains the top cause of death and disease around the globe, but the risks are not shared equally, according to the latest assessment from the Global Burden of Disease (GBD) ...

In people with a recent diagnosis of type 2 diabetes (T2D) and no prior cardiovascular disease (CVD), self-reported physical activity was independently associated with major adverse cardiac events ...